CQ HealthBeat reports.

Related StoriesMembers enrolled in Medicare Advantage content with their plans, research findsASTRO worried about proposed Medicare physician payment cuts to radiation therapyCost of radiation therapy varies broadly among Medicare sufferers with cancerIn a separate letter sent to Waxman on Thursday, the Pharmaceutical Care Management Association – – the lobby that represents PBMs – – stated that release of the data would increase prices for the drug benefit and beneficiaries. Association spokesperson Phil Blando said, ‘To the extent that any information is supplied to the committee, whether from CMS or individual companies, we think it’s vital that the committee safeguard the information’ . This article is definitely republished with kind authorization from our close friends at the The Kaiser Family members Foundation.‘We are delighted to formally release our collaboration with CIRM for the advancement of AST-OPC1 neural cells as a potential pluripotent stem-cell based therapy for spinal-cord injury,’ stated Pedro Lichtinger, CEO and President of Asterias. ‘The signing of the Notice of Grant Award was the last in a series of milestones necessary to begin the launch of funds under the CIRM grant.august 2014 ‘ In, Asterias received clearance from the U.S. Meals and Drug Administration to initiate the Phase 1/2a clinical trial of AST-OPC1. The approved trial follows the successful completion of the Phase 1 clinical study of the product, which met its primary endpoints of basic safety and feasibility when administered to five patients with neurologically-complete, thoracic spinal cord injury.